ECSP088813A - Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 - Google Patents

Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2

Info

Publication number
ECSP088813A
ECSP088813A EC2008008813A ECSP088813A ECSP088813A EC SP088813 A ECSP088813 A EC SP088813A EC 2008008813 A EC2008008813 A EC 2008008813A EC SP088813 A ECSP088813 A EC SP088813A EC SP088813 A ECSP088813 A EC SP088813A
Authority
EC
Ecuador
Prior art keywords
pharmaceutically acceptable
solvate
hydrate
inflammation
allergic
Prior art date
Application number
EC2008008813A
Other languages
English (en)
Inventor
Timothy Alan Gillespy
Keith John Harris
David Stefany
Charles J Gardner
Joacy C Aguiar
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP088813A publication Critical patent/ECSP088813A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La presente invención se refiere a un compuesto de fórmula (I), en la que R1 y R2 son como se han definido en este documento, o una sal farmacéuticamente aceptable, hidrato o solvato del mismo, un profármaco farmacéuticamente aceptable del mismo, o una sal farmacéuticamente aceptable, hidrato o solvato del profármaco, una composición farmacéutica que comprende una cantidad farmacéuticamente eficaz de uno o más compuestos de la invención mezclada con un vehículo farmacéuticamente aceptable, un método para tratar a un paciente que padece un trastorno mediado por PGD2 incluyendo, pero sin limitación, enfermedad alérgica (tal como rinitis alérgica, conjuntivitis alérgica, dermatitis atópica, asma bronquial y alergia alimentaria), mastocitosis sistémica, trastornos acompañados por la activación sistémica de mastocitos, choque anafiláctico, broncoconstricción, bronquitis, urticaria, eccema, enfermedades acompañadas por picor (tales como dermatitis atópica y urticaria), enfermedades (tales como cataratas, desprendimiento de retina, inflamación, infección y trastornos del sueño) que se generan secundariamente como resultado del comportamiento que acompaña al picor (tal como rascarse y golpearse), inflamación, enfermedad pulmonar obstructiva crónica, lesión por isquemia-reperfusión, accidente cerebrovascular, artritis reumatoide crónica, pleuritis, colitis ulcerosa y similares, por medio de la administración a dicho paciente de una cantidad farmacéuticamente eficaz de un compuesto de la invención.
EC2008008813A 2006-04-12 2008-10-09 Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 ECSP088813A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74467606P 2006-04-12 2006-04-12

Publications (1)

Publication Number Publication Date
ECSP088813A true ECSP088813A (es) 2008-11-27

Family

ID=38294040

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008813A ECSP088813A (es) 2006-04-12 2008-10-09 Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2

Country Status (26)

Country Link
US (1) US20090036469A1 (es)
EP (1) EP2010503A1 (es)
JP (1) JP2009533473A (es)
KR (1) KR20080108287A (es)
CN (1) CN101421252B (es)
AR (1) AR060403A1 (es)
AU (1) AU2007238052B2 (es)
BR (1) BRPI0710710A2 (es)
CA (1) CA2649083C (es)
CR (1) CR10249A (es)
DO (1) DOP2007000068A (es)
EC (1) ECSP088813A (es)
HK (1) HK1131975A1 (es)
HN (1) HN2008001530A (es)
MA (1) MA30409B1 (es)
MX (1) MX2008011369A (es)
NO (1) NO20084291L (es)
NZ (1) NZ571793A (es)
PE (1) PE20080186A1 (es)
RU (1) RU2431631C2 (es)
TN (1) TNSN08339A1 (es)
TW (1) TW200815395A (es)
UA (1) UA95950C2 (es)
UY (1) UY30283A1 (es)
WO (1) WO2007121280A1 (es)
ZA (1) ZA200807380B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5039594B2 (ja) * 2008-02-08 2012-10-03 株式会社日立ハイテクノロジーズ レビュー装置，検査領域設定支援システム、および、欠陥の画像得方法
TW201034675A (en) * 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
CA2793324A1 (en) * 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. A substituted pyrimidine as a prostaglandin d2 receptor antagonist
TW201200133A (en) * 2010-03-16 2012-01-01 Aventis Pharma Inc Substituted pyrimidines as prostaglandin D2 receptor antagonists
JP5800898B2 (ja) 2010-07-05 2015-10-28 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル−置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
US8785467B2 (en) * 2010-09-30 2014-07-22 Merck Sharp & Dohme Corp. Alkoxy pyrimidine PDE10 inhibitors
EP2794563B1 (en) 2011-12-21 2017-02-22 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2885307A1 (en) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
WO2014066568A1 (en) 2012-10-24 2014-05-01 Winthrop-University Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
RU2673084C2 (ru) * 2013-11-08 2018-11-22 Киссеи Фармасьютикал Ко., Лтд. Производное карбоксиметилпиперидина
CN106661002B (zh) 2014-08-04 2021-06-29 纽韦卢森公司 用于治疗炎性、代谢性、肿瘤性和自身免疫性疾病的嘧啶衍生物
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
ES2896476T3 (es) 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
AU2018269666B2 (en) 2017-05-18 2022-02-03 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
TW201900178A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之嘧啶衍生物
SG11202002065VA (en) 2017-09-13 2020-04-29 Progenity Inc Preeclampsia biomarkers and related systems and methods
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
JP2023519603A (ja) 2020-03-31 2023-05-11 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
AU2021249530A1 (en) 2020-03-31 2022-12-01 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3644799A1 (de) * 1986-06-04 1987-12-10 Hoechst Ag Neue pyrimidin-derivate, deren herstellung und verwendung
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200600457A (es) * 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2

Also Published As

Publication number Publication date
HK1131975A1 (en) 2010-02-12
CA2649083C (en) 2011-06-28
NO20084291L (no) 2008-11-11
ZA200807380B (en) 2009-05-27
CR10249A (es) 2008-11-26
HN2008001530A (es) 2012-01-17
CA2649083A1 (en) 2007-10-25
MA30409B1 (fr) 2009-05-04
AR060403A1 (es) 2008-06-11
UA95950C2 (en) 2011-09-26
TW200815395A (en) 2008-04-01
CN101421252B (zh) 2011-10-12
CN101421252A (zh) 2009-04-29
RU2008144578A (ru) 2010-05-20
NZ571793A (en) 2011-08-26
DOP2007000068A (es) 2007-10-31
AU2007238052B2 (en) 2011-12-22
JP2009533473A (ja) 2009-09-17
PE20080186A1 (es) 2008-04-15
KR20080108287A (ko) 2008-12-12
WO2007121280A1 (en) 2007-10-25
US20090036469A1 (en) 2009-02-05
MX2008011369A (es) 2008-09-18
EP2010503A1 (en) 2009-01-07
UY30283A1 (es) 2007-11-30
BRPI0710710A2 (pt) 2011-08-16
TNSN08339A1 (en) 2009-12-29
AU2007238052A1 (en) 2007-10-25
RU2431631C2 (ru) 2011-10-20

Similar Documents

Publication Publication Date Title
ECSP088813A (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
DOP2006000220A (es) Sal de dihidrógeno fosfato de un antagonista del receptor de prostaglandina d2
DOP2006000016A (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
ECSP099087A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
TNSN07098A1 (en) 2,6- substituted -4- monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
NO20083567L (no) Hydantoinderivater for behandling av inflammatoriske forstyrrelser
NO20091489L (no) Tiazolpyrazolopyridiner som CRF1 reseptorantagonister
EA200970852A1 (ru) Производные пиразоло[3,4-в]пиридина в качестве ингибиторов фосфодиэстеразы
MX365781B (es) Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas.
JP2019505500A (ja) 哺乳類ヒストンデアセチラーゼ活性の阻害剤として有用な二環式ヒドロキサム酸
MX2009003100A (es) Inhibidores de fosfodiesterasa tipo iv.
MX2012007711A (es) Compuestos de piruvamida como inhibidores de alergeno de peptidasa del grupo 1 de acaros del polvo.
WO2009115874A3 (en) Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation
MX2013002462A (es) Compuestos heterociclicos como inhibidores de dgat1.
DOP2009000009A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
UA95303C2 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
TH100504B (th) อินโดลคาร์บอกซาไมด์เป็นสารยับยั้ง ikk2
UY30505A1 (es) Fenilindoles como antagonistas del receptor de la prostaglandina d2
TH117954A (th) สารประกอบเฮเทอโรไซคลิค
CY1113582T1 (el) 2,6-υποκατεστημενες-4-μονοϋποκατεστημενες amino-πυριμιδινες ως ανταγωνιστες υποδοχεων d2 των προσταγλανδινων
TH117954B (th) สารประกอบเฮเทอโรไซคลิค